A drug commonly used to avoid or prevent bloodstream from clotting.

The work was supported by the National Institutes of Health and the American Heart Association. Rensselaer and UNC-Chapel Hill possess filed a provisional patent on the procedure jointly. Linhardt said additional research will seek to scale the procedure another million-fold to make it commercially viable.. Alternative method to produce heparin Researchers in Rensselaer Polytechnic Institute and University of North Carolina at Chapel Hill can see an alternative way to produce heparin, a drug commonly used to avoid or prevent bloodstream from clotting. The results could enable the existing way to obtain the drug – right now extracted from animal tissue – to be changed or supplemented by the artificial version. The new process also can be employed as a tool for drug discovery, according to the researchers.The collaboration between St and ChromaDex. Jude will focus on screening ChromaDex's organic item libraries against certain biological assays and tumor models with the intent of identifying high value, patentable natural products for specific therapeutic indications potentially. Jude will screen the natural product libraries supplied by ChromaDex, and also perform other chemical substance assays to further the characterization of the compounds provided.